View Older Stories View More Recent Stories

Sep 29, 2015 10:30AM International Coalition Urges Final Push to Eliminate River Blindness from the Americas
Sep 29, 2015 08:10AM EMD Serono Joins Industry Leaders for The Economist Events' War On Cancer Forum in Boston
Sep 28, 2015 08:00AM Syndax And Merck Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And KEYTRUDA®
Sep 28, 2015 07:30AM MARIZEV® (Omarigliptin), Merck’s Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
Sep 27, 2015 07:00AM New Data from KEYNOTE-028, Merck’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
Sep 26, 2015 07:00AM New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma
Sep 25, 2015 08:00AM Merck to Hold Third-Quarter 2015 Sales and Earnings Conference Call on October 27
Sep 21, 2015 08:00AM Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...
Sep 20, 2015 12:30PM Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
Sep 18, 2015 03:00PM Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
Sep 17, 2015 08:30AM Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes
Sep 16, 2015 10:16AM Merck’s Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA® (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin
Sep 16, 2015 08:00AM Merck to Participate at the Morgan Stanley Global Healthcare Conference
Sep 16, 2015 07:30AM Merck Highlights Its Commitment to Infectious Disease with 40 Presentations of Data at ICAAC/ICC 2015
Sep 10, 2015 09:00AM Merck Publishes 2014 Global Corporate Responsibility Report
Sep 8, 2015 08:30AM Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept), a Biosimilar of Enbrel, in Korea
Sep 2, 2015 08:00AM FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents
Sep 1, 2015 09:00AM New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Aug 20, 2015 08:30AM New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Will Be Presented at the European Society
Aug 18, 2015 01:17PM Merck Recalls TEMODAR® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child–Resistant Closure Requirement
Aug 18, 2015 08:00AM FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
Aug 14, 2015 08:00AM Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal
Aug 13, 2015 08:00AM Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
Aug 10, 2015 08:00AM Immune Design and Merck to Collaborate on Combination Trials of Two Immune Design Immunotherapies With Merck's KEYTRUDA for Non-Hodgkin's Lymphoma and Melanoma
Aug 10, 2015 08:00AM Immune Design and Merck to Collaborate on Combination Trials of Two Immune Design Immunotherapies With Merck's KEYTRUDA for Non-Hodgkin's Lymphoma and Melanoma
Jul 31, 2015 08:10AM In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing
Jul 30, 2015 08:00AM Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal
Jul 28, 2015 04:15PM Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors
Jul 28, 2015 07:42AM Wall Street bounces back after five-day selloff
Jul 28, 2015 07:00AM Merck Announces Second-Quarter 2015 Financial Results
Jul 28, 2015 06:45AM Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
Jul 28, 2015 06:30AM Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infe
Jul 27, 2015 02:13PM Trading Radar for 7/28: Ford (F), Twitter (TWTR) DuPont (DD), Pfizer (PFE), UPS (UPS), US Steel (X) Report
Jul 27, 2015 08:30AM Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA™ (Ceftolozane and Tazobactam)
Jul 23, 2015 11:02AM Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection
Jul 22, 2015 01:28PM Merck Announces Fourth-Quarter 2015 Dividend
Jul 22, 2015 07:00AM European Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma
Jul 21, 2015 08:00AM Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS
Jul 15, 2015 08:00AM Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal
Jul 7, 2015 07:00AM Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program
Jun 29, 2015 08:30AM Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiv
Jun 26, 2015 08:00AM Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28
Jun 11, 2015 09:00AM Liaison Technologies and Merck Cut the Ribbon for a Collaborative Innovation Center on NC State's Centennial Campus
Jun 11, 2015 08:00AM Merck Launches New Program That Encourages Women to "Rule the Real Talk" and Prioritize Their Sexual Health
Jun 10, 2015 08:46AM Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints
Jun 8, 2015 04:30PM TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
Jun 3, 2015 05:00PM Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine
Jun 1, 2015 04:34PM FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Non-Small Cell Lung Cancer, and Grants Priority Review
Jun 1, 2015 08:30AM Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
Jun 1, 2015 08:00AM Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
View More Recent Stories View Older Stories